Flipkart's outgoing Chief Product and Technology Officer (CPTO), Jeyandran Venugopal, is expected to join Reliance Retail Ventures as its Chief Executive Officer (CEO). Venugopal, who resigned ...

The official launch event took place under the presidency of Chea Serey, NBC governor, and Dato’ Seri Abdul Rasheed Ghaffour, BNM governor, during the ASEAN Finance Ministers' and Central Bank ...

Mumbai: Speculations are rife with reports that Jeyandran Venugopal will be joining Reliance Retail (RRVL) as their CEO. The appointment is under consideration currently and is expected to be ...

Flipkart’s outgoing chief product and technology officer (CPTO) Jeyandran Venugopal will likely join Reliance Retail Ventures as chief executive. Venugopal resigned from Flipkart in February ...

Former prime minister Dr Mahathir Mohamad decried “slander” after being accused of refusing to sign off on the transfer of Umno land that he is holding in trust for the party. He said that ...

Jeyandran Venugopal, Flipkart’s outgoing Chief Product and Technology Officer, is expected to join Reliance Retail Ventures (RRV) as its Chief Executive Officer, according to an Economic Times ...

Magistrate Nur Eleana Dato Seri Paduka Hairol Arni noted that Rasiah had shown limited remorse, offering an unsubstantiated claim that she had partially repaid one victim, and explained her ...

In February, Jeyandran Venugopal resigned from the post of CPTO at Flipkart after a six-year long tenure. Founded in 2007 by Mukesh Bansal, Ashutosh Lawania and Vineet Saxena, Myntra operates a ...

PUTRAJAYA: Chinese President Xi Jinping has arrived at the Seri Perdana Complex to meet Prime Minister Datuk Seri Anwar Ibrahim to exchange views on various issues. Anwar warmly welcomed Xi and ...

On February 5, Moneycontrol had reported that Jeyandran Venugopal, CPTO at Flipkart, was leaving after an eight-year-long tenure. "After a stint of over five years, Raghu has decided to explore ...

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...